Brokerages expect that NeoGenomics, Inc. (NASDAQ:NEO) will report earnings per share (EPS) of $0.03 for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for NeoGenomics’ earnings. The lowest EPS estimate is $0.02 and the highest is $0.03. NeoGenomics posted earnings per share of $0.01 during the same quarter last year, which would indicate a positive year-over-year growth rate of 200%. The firm is expected to announce its next earnings results on Wednesday, October 24th.
On average, analysts expect that NeoGenomics will report full-year earnings of $0.15 per share for the current financial year, with EPS estimates ranging from $0.12 to $0.17. For the next fiscal year, analysts expect that the business will post earnings of $0.23 per share, with EPS estimates ranging from $0.18 to $0.30. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research firms that cover NeoGenomics.
NeoGenomics (NASDAQ:NEO) last announced its quarterly earnings results on Tuesday, July 24th. The medical research company reported $0.05 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.04 by $0.01. NeoGenomics had a negative return on equity of 0.36% and a negative net margin of 0.98%. The business had revenue of $67.70 million for the quarter, compared to analyst estimates of $66.40 million. During the same quarter in the prior year, the company posted $0.04 EPS. The company’s quarterly revenue was up 8.7% on a year-over-year basis.
In related news, EVP Steven C. Jones sold 44,600 shares of the stock in a transaction dated Monday, July 30th. The stock was sold at an average price of $14.01, for a total transaction of $624,846.00. Following the transaction, the executive vice president now owns 241,815 shares of the company’s stock, valued at approximately $3,387,828.15. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Steven C. Jones sold 203,500 shares of the stock in a transaction dated Wednesday, August 1st. The stock was sold at an average price of $14.00, for a total value of $2,849,000.00. Following the transaction, the insider now directly owns 241,815 shares in the company, valued at approximately $3,385,410. The disclosure for this sale can be found here. 12.20% of the stock is currently owned by corporate insiders.
A number of institutional investors and hedge funds have recently bought and sold shares of NEO. OMERS ADMINISTRATION Corp acquired a new position in NeoGenomics during the 1st quarter worth about $152,000. Cubist Systematic Strategies LLC acquired a new position in NeoGenomics during the 2nd quarter worth about $171,000. AMP Capital Investors Ltd acquired a new position in NeoGenomics during the 2nd quarter worth about $178,000. PNC Financial Services Group Inc. acquired a new position in NeoGenomics during the 2nd quarter worth about $272,000. Finally, WINTON GROUP Ltd acquired a new position in NeoGenomics during the 1st quarter worth about $338,000. 81.06% of the stock is currently owned by hedge funds and other institutional investors.
Shares of NeoGenomics stock opened at $15.38 on Friday. NeoGenomics has a 52 week low of $7.08 and a 52 week high of $15.49. The firm has a market capitalization of $1.22 billion, a PE ratio of 256.33 and a beta of 0.58. The company has a current ratio of 1.74, a quick ratio of 1.59 and a debt-to-equity ratio of 0.77.
NeoGenomics Company Profile
NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States. It operates through Clinical Services and Pharma Services segments. The company laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, and other clinical laboratories.
Recommended Story: How to calculate the intrinsic value of a stock
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.